PRECIGEN, INC. (PGEN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 29.35M USD | Liabilities, Current |
| Cash and equivalents | 16.33M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 71.87M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $29.35M | $16.33M | (m) | $71.87M | (m) | (m) |
| 2026-03-31 | (m) | $21.10M | $7.48M | (m) | $26.40M | (m) | (m) |
| 2025-12-31 | (m) | $37.31M | $30.23M | (m) | $3.92M | (m) | (m) |
| 2025-09-30 | (m) | $32.07M | $14.32M | (m) | $580.00K | (m) | (m) |
| 2025-06-30 | (m) | $23.19M | $13.76M | (m) | $327.00K | (m) | (m) |
| 2025-03-31 | (m) | $23.99M | $6.06M | (m) | $751.00K | (m) | (m) |
| 2024-12-31 | (m) | $21.52M | $29.52M | (m) | $926.00K | (m) | (m) |
| 2024-09-30 | (m) | $21.22M | $24.73M | (m) | $479.00K | (m) | (m) |
| 2024-06-30 | (m) | $23.02M | $9.35M | (m) | $511.00K | (m) | (m) |
| 2024-03-31 | (m) | $28.77M | $17.48M | (m) | $872.00K | (m) | (m) |
| 2023-12-31 | (m) | $22.98M | $7.58M | (m) | $902.00K | (m) | (m) |
| 2023-09-30 | (m) | $32.88M | $10.08M | (m) | $988.00K | (m) | (m) |
| 2023-06-30 | (m) | $30.77M | $16.55M | (m) | $1.35M | (m) | (m) |
| 2023-03-31 | (m) | $46.73M | $9.74M | (m) | $1.77M | (m) | (m) |
| 2022-12-31 | (m) | $78.64M | $4.86M | (m) | $959.00K | (m) | (m) |
| 2022-09-30 | (m) | $104.86M | $9.07M | (m) | $1.18M | (m) | (m) |
| 2022-06-30 | (m) | $29.90M | $43.84M | (m) | $1.31M | (m) | (m) |
| 2022-03-31 | (m) | $25.60M | $40.32M | (m) | $24.31M | (m) | (m) |
| 2021-12-31 | (m) | $34.65M | $42.92M | (m) | $20.83M | (m) | (m) |
| 2021-09-30 | (m) | $28.99M | $41.73M | (m) | $20.17M | (m) | (m) |
| 2021-06-30 | (m) | $28.87M | $36.41M | (m) | $26.02M | (m) | (m) |
| 2021-03-31 | (m) | $25.24M | $27.36M | (m) | $20.79M | (m) | (m) |
| 2020-12-31 | (m) | $42.13M | $51.79M | (m) | $16.49M | (m) | (m) |
| 2020-09-30 | (m) | $30.66M | $27.74M | (m) | $19.06M | (m) | (m) |
| 2020-06-30 | (m) | $64.10M | $46.71M | (m) | $23.34M | (m) | (m) |
| 2020-03-31 | (m) | $70.64M | $37.84M | (m) | $19.38M | (m) | (m) |
| 2019-12-31 | (m) | $122.91M | $65.79M | (m) | $20.65M | (m) | (m) |
| 2019-09-30 | (m) | $81.95M | $44.43M | (m) | $20.41M | (m) | (m) |
| 2019-06-30 | (m) | $51.63M | $58.16M | (m) | $24.50M | (m) | (m) |
| 2019-03-31 | (m) | $59.42M | $106.54M | (m) | $19.86M | (m) | (m) |
| 2018-12-31 | (m) | $61.56M | $102.77M | (m) | $21.20M | (m) | (m) |
| 2018-09-30 | (m) | $92.33M | $82.42M | (m) | $18.16M | (m) | (m) |
| 2018-06-30 | (m) | $83.25M | $78.47M | (m) | $22.62M | (m) | (m) |
| 2018-03-31 | (m) | $86.85M | $119.93M | (m) | $17.70M | (m) | (m) |
| 2017-12-31 | (m) | $80.17M | $68.11M | (m) | $19.77M | (m) | (m) |
| 2017-09-30 | (m) | $87.80M | $64.22M | (m) | $18.13M | (m) | (m) |
| 2017-06-30 | (m) | $95.69M | $64.36M | (m) | $22.83M | (m) | (m) |
| 2017-03-31 | (m) | $90.65M | $69.85M | (m) | $19.70M | (m) | (m) |
| 2016-12-31 | (m) | $94.61M | $62.61M | (m) | $21.64M | (m) | (m) |
| 2016-09-30 | (m) | $100.52M | $69.71M | (m) | $22.03M | (m) | (m) |
| 2016-06-30 | (m) | $95.50M | $155.08M | (m) | $27.03M | (m) | (m) |
| 2016-03-31 | (m) | $77.94M | $145.73M | (m) | $21.87M | (m) | (m) |
| 2015-12-31 | (m) | $75.90M | $135.78M | (m) | $25.10M | (m) | (m) |
| 2015-09-30 | (m) | $77.09M | $125.43M | (m) | $25.15M | (m) | (m) |
| 2015-06-30 | (m) | $122.81M | $98.90M | (m) | $141.13M | (m) | (m) |
| 2015-03-31 | (m) | $48.70M | $99.02M | (m) | $15.00M | (m) | (m) |
| 2014-12-31 | (m) | $47.48M | $27.47M | (m) | $14.58M | (m) | (m) |
| 2014-09-30 | (m) | $39.26M | $24.70M | (m) | $15.27M | (m) | (m) |
| 2014-06-30 | (m) | $20.69M | $74.50M | (m) | $806.00K | (m) | (m) |
| 2014-03-31 | (m) | $22.21M | $110.05M | (m) | $695.00K | (m) | (m) |
| 2013-12-31 | (m) | $19.83M | $49.51M | (m) | $790.00K | (m) | (m) |
| 2013-09-30 | (m) | $19.72M | $61.22M | (m) | $195.00K | (m) | (m) |
| 2013-06-30 | (m) | $17.51M | $34.46M | (m) | $258.00K | (m) | (m) |
| 2013-03-31 | (m) | (m) | $59.72M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $16.72M | $10.40M | (m) | $141.00K | (m) | (m) |
| 2012-09-30 | (m) | (m) | $4.08M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $19.33M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $19.63M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $17.37M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |